AI Analysis | Feedback

Here are 1-2 brief analogies for Atossa Therapeutics:

• A small biotech developing new drugs, like a **startup Genentech** for cancer treatments.

• A clinical-stage drug developer, like an **early-stage Gilead Sciences** focused on both cancer and infectious diseases.

AI Analysis | Feedback

• Endoxifen: An active metabolite of tamoxifen in Phase II clinical trials to treat and prevent breast cancer.
• AT-H201: An inhalation therapy designed to improve lung function in severely ill and hospitalized COVID-19 patients.
• AT-301: A proprietary drug candidate for nasal administration in patients diagnosed with COVID-19.
• Immunotherapy/Chimeric Antigen Receptor Therapy Programs: Therapeutic programs being developed for the treatment of breast cancer.

AI Analysis | Feedback

Atossa Therapeutics (ATOS) is a clinical-stage biopharmaceutical company. This means that the company is primarily focused on the discovery, development, and testing of new drug candidates through clinical trials. As described, their lead program, Endoxifen, is in Phase II clinical trials, and other drug candidates (AT-H201, AT-301) are also in development.

Because Atossa Therapeutics does not yet have any approved commercial products on the market, it does not currently have "major customers" in the traditional sense of selling products or services to other companies or individuals.

Therefore, Atossa Therapeutics does not currently have major customers to list.

AI Analysis | Feedback

AI Analysis | Feedback

Steven C. Quay MD, PHD Chairman of the Board and Chief Executive Officer

Dr. Steven C. Quay is the founder of Atossa Therapeutics, Inc., established in 2009. He is a physician-scientist and biotech entrepreneur who has founded six startups. Dr. Quay is credited with inventing seven FDA-approved pharmaceuticals that have been used by over 80 million people worldwide. He holds 91 to 94 U.S. patents for inventions in various medical fields. He has been recognized as an Entrepreneur of the Year by Ernst & Young for two companies. His academic background includes faculty positions at Harvard Medical School and Stanford University School of Medicine, and he was a postdoctoral fellow at the Massachusetts Institute of Technology with Nobel Laureate H. Gobind Khorana.

Mark Daniel Chief Financial Officer

Mark Daniel was appointed Chief Financial Officer of Atossa Therapeutics, Inc. on October 14, 2025. He brings over 25 years of experience in life-sciences finance, including expertise in revenue forecasting, public company controls, and capital markets. His experience includes managing weekly revenue forecasting, overseeing operating expense budgets exceeding $200 million, implementing Sarbanes-Oxley controls, and leading cost-saving programs. Mr. Daniel's capital markets experience includes managing a $400 million cash and investments portfolio and participating in nearly $1 billion in equity, convertible debt, and credit transactions. Prior to joining Atossa, he served as Senior Vice President, Finance at Bruker Spatial Biology, Inc. from 2017 to 2025, and as Chief Financial Officer of Newyu, Inc. (formerly Numera, Inc.) from 2014 to 2016.

Delly Behen Senior Vice President, Business Operations

Delly Behen has served as Atossa's Senior Vice President, Business Operations since July 2014. She has over 20 years of human resources, administrative, and operational experience, including leading people, culture, and administration at various biotech companies in the Puget Sound area. Before her current role, she served as an HR Consultant for Impel NeuroPharma and held positions with increasing responsibilities at CTI Biopharma. She also worked as Director of Human Resources at Atossa Genetics, Inc. from 2014 to 2015, prior to the company changing its name.

Janet R. Rea, MSPH Senior Vice President, Research & Development

Janet R. Rea was appointed Senior Vice President, R&D in October 2025, a newly created position at Atossa Therapeutics, Inc. She brings more than two decades of strategic research and clinical development expertise, with a successful record in regulatory approvals. Ms. Rea previously served as Senior Vice President, Regulatory, Quality, and Clinical Affairs at Atossa, where she secured regulatory clearance for and executed clinical studies of (Z)-endoxifen in Australia, the U.S., and Sweden. Her career includes senior development leadership roles at AVM Biotechnology (COO, SVP), TPI Therapeutics, and Protein Sciences Corporation (acquired by Sanofi/Glaxo), where she played a key role in the approval of FluBlok®, an innovative rDNA egg-free influenza vaccine. She also served as an Assistant Professor at the University of Washington, Department of Pharmacy.

Bernadine Heather Fraser VP-Clinical, Regulatory & CMC Division

Bernadine Heather Fraser holds the position of VP-Clinical, Regulatory & CMC Division at Atossa Therapeutics, Inc. since 2020. Prior to joining Atossa, she worked as Senior Director-Preclinical & Clinical Sciences at Anthera Pharmaceuticals, Inc. from 2006 to 2012. She also served as the VP-Clinical Operations & Project Management at Avalo Therapeutics, Inc. in 2012. Dr. Fraser obtained a doctorate degree from the University of Alberta.

AI Analysis | Feedback

Clinical Trial and Regulatory Approval Risk: Atossa Therapeutics is a clinical-stage biopharmaceutical company with its lead program, Endoxifen, in Phase II clinical trials, and other candidates like AT-H201 and AT-301 also in development. The success of the company's business model is critically dependent on the successful completion of extensive clinical trials for its drug candidates, followed by obtaining the necessary regulatory approvals from health authorities. Failure at any stage of clinical development (Phase II, Phase III), unexpected adverse events, or an inability to demonstrate sufficient efficacy could lead to delays, increased costs, or even the complete termination of a development program. Similarly, regulatory bodies may not grant approval even if trials are successful, posing a significant hurdle to commercialization.

Financing Risk: As a company without any approved commercial products generating revenue, Atossa Therapeutics relies on its ability to raise capital to fund its ongoing research and development activities, including expensive clinical trials, and general operations. The company's future success is contingent upon its ability to obtain additional financing through equity offerings, debt financing, or partnerships. A failure to secure adequate funding in a timely manner could severely impact its ability to continue developing its drug candidates, pursue regulatory approvals, or even maintain operations.

Competition Risk: Atossa Therapeutics operates in highly competitive therapeutic areas, including oncology (breast cancer, CAR-T therapies) and infectious diseases (COVID-19 treatments). The landscape is populated by numerous pharmaceutical and biotechnology companies, many of which have significantly greater financial, technical, and human resources, as well as more established product pipelines and marketing capabilities. Even if Atossa's drug candidates successfully complete clinical trials and receive regulatory approval, they will face intense competition from existing treatments and new therapies being developed by competitors, which could limit market adoption, pricing power, and overall commercial success.

AI Analysis | Feedback

null

AI Analysis | Feedback

AI Analysis | Feedback

Atossa Therapeutics, Inc. (ATOS), a clinical-stage biopharmaceutical company, anticipates its future revenue growth over the next 2-3 years to be primarily driven by the advancement and potential commercialization of its lead product candidate, (Z)-endoxifen, across multiple indications.

Here are 3-5 expected drivers of future revenue growth:

1. Regulatory Approval and Commercialization of (Z)-Endoxifen for Metastatic Breast Cancer: Atossa Therapeutics is actively pursuing the development of (Z)-endoxifen for estrogen receptor-positive, HER2-negative metastatic breast cancer. The U.S. Food and Drug Administration (FDA) issued a "Study May Proceed" letter in January 2026, allowing the company to advance clinical testing for this indication. Atossa is focused on generating New Drug Application (NDA)-enabling data in 2026, positioning this program as a significant potential revenue driver upon successful approval and market launch.

2. Regulatory Approval and Commercialization of (Z)-Endoxifen for Breast Cancer Risk Reduction and Neoadjuvant/Adjuvant Settings: The company is strategically working with the FDA to accelerate the development of low-dose (Z)-endoxifen for breast cancer risk reduction, including its use in the adjuvant setting (post-surgery recurrence risk-reduction), in ductal carcinoma in situ (DCIS), and for high-risk women without cancer. Ongoing Phase 2 trials, such as EVANGELINE, are being streamlined to accelerate objective readouts and prioritize NDA-enabling activities in 2026. Positive results from these trials and subsequent regulatory approvals would open up substantial market opportunities.

3. Potential Monetization of a Priority Review Voucher (PRV) from (Z)-Endoxifen in Duchenne Muscular Dystrophy (DMD): In January 2026, the FDA granted Rare Pediatric Disease designation to (Z)-endoxifen for the treatment of Duchenne Muscular Dystrophy. This designation makes the drug candidate eligible for a Priority Review Voucher upon FDA approval, which is a transferable asset that can be sold to other pharmaceutical companies, providing a significant source of non-product revenue.

AI Analysis | Feedback

Share Issuance

• Atossa Therapeutics authorized the sale of common stock up to an aggregate offering price of $100,000,000 through an Open Market Sale Agreement with Jefferies LLC, effective November 19, 2024.
• The number of shares outstanding for Atossa Therapeutics significantly increased by 1145.11% in 2021.
• The company's shares outstanding increased by 2.7% in 2025 and 2.39% in the last year.

Capital Expenditures

• In the last 12 months, capital expenditures for Atossa Therapeutics were approximately -$16,000.
• Capital expenditures were approximately $16,000, representing a -15.8% year-over-year change between June and December 2023.
• Atossa Therapeutics invested $7,000 in capital expenditures in Q3 2025, which primarily funded long-term assets and infrastructure.